GlassScriptPhysician profile
Rajasekhar Jupalli
NPI 1760557326
$568.56
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $189 · 2021: $60.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $110.65 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $99.48 | 2019 | |
| Sunovion Pharmaceuticals INC. | $83.90 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $50.55 | 2020 | |
| Abbvie INC. | $32.45 | 2021 | |
| Acadia Pharmaceuticals INC | $31.62 | 2019 | |
| Allergan, INC. | $29.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.46 | 2020 | |
| Neuronetics, INC. | $24.74 | 2019 | |
| Lundbeck LLC | $20.78 | 2020 | |
| Jazz Pharmaceuticals INC. | $19.51 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.04 | 2021 | |
| Ironshore Pharmaceuticals INC. | $12.95 | 2020 | |
| Indivior INC. | $12.50 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajasekhar Jupalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.